Vitamin d may unlock iron absorption in IBD patients

NCT ID NCT07673497

Disease control Sponsor: Gazi University Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates whether giving vitamin D supplements to adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who also have low vitamin D levels can improve their iron status. Participants take high-dose vitamin D3 weekly for 8 weeks, then a lower daily dose, and are checked after 3 months. The goal is to see if correcting vitamin D deficiency helps the body use iron better, potentially reducing the need for iron infusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Vitamin D3 (cholecalciferol)
What this could lead to: If it works, this could point toward a simple vitamin D supplement to help manage iron deficiency in people with IBD.
What could go wrong: This is a small pilot study with only 43 participants and no placebo group, so results may not be conclusive or apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

43 people

The number who actually took part.

Started

Sep 2022

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who are 18 years of age or older 2. Patients who agreed to participate in the study 3. Patients diagnosed with Ulcerative Colitis 4. Patients diagnosed with Crohn's Disease 5. Patients with vitamin D levels \<20 ng/ml\[11\] 6. Crohn's patients with a Harvey Bradshaw Index below 5\[9\] 7. Ulcerative colitis patients in clinical remission, defined as a partial Mayo Score ≤1 with no individual subscore \>1\[10\]. Exclusion Criteria: 1. Patients who are under 18 years of age 2. Patients with vitamin D or Iron allergy 3. Crohn's patients with a Harvey Bradshaw Index of 5 or higher 4. Ulcerative colitis patients with a partial Mayo Score \>1, or any individual subscore \>1 5. Patients with fever

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammatory bowel disease (Crohn's disease; ulcerative colitis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease Iron Deficiencies ulcerative colitis vitamin D deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammatory bowel disease (Crohn's disease; ulcerative colitis) Iron deficiency and overload Vitamin D

Vitamin d may unlock iron absorption in IBD patients

What the study statuses mean